Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

被引：36

作者：

Thompson, R. Houston

Allison, James P.

Kwon, Eugene D. ^{[1
]}

机构：

[1] Mayo Clin & Mayo Grad Sch Med, Dept Urol, Rochester, MN 55905 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10021 USA

[3] Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2006年 / 24卷 / 05期

关键词：

prostatic neoplasms; immunotherapy; T-lymphocyte; costimulation; CTLA-4;

D O I：

10.1016/j.urolonc.2005.08.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Costimulatory pathway ligands and receptors can deliver either positive or negative signals to help determine the ultimate fate of activated T lymphocytes. Cytotoxic T lymphocyte antigen-4 (CTLA-4) represents one of the most extensively studied receptors in the costimulatory pathway and has recently been shown to function as a potent inhibitor of T cell-mediated immunity. T-cell expression of CTLA-4 indirectly facilitates tumor progression by restraining host antitumoral immunity. In contrast, administration of a monoclonal antibody to block CTLA-4 function can alleviate restraints on T-cell activity to promote immune-mediated tumor regression. We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：442 / 447

页数：6

共 43 条

[1] B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation [J].